



GEORGIA DEPARTMENT
OF COMMUNITY HEALTH

Georgia Department of Community Health

DRUG UTILIZATION REVIEW BOARD MEETING

Department of Community Health
2 Peachtree Street – **5th Floor Board Room**
Atlanta, Georgia 30303

August 6, 2019

This page intentionally left blank



DRUG UTILIZATION REVIEW BOARD MEETING

AGENDA

2 Peachtree Street - 5th Floor DCH Board Room

Atlanta, Georgia 30303

Tuesday, August 6, 2019

10:00 a.m. to 2:00 p.m.

CALL TO ORDER	<i>Celeste Fowler, PharmD, Vice-Chair</i>
MINUTES FROM PREVIOUS MEETING	<i>Vice-Chair</i>
EXTERNAL COMMENTS SESSION	<i>Vice-Chair</i>
CLINICAL REVIEWS	<i>Afzal Mistry, PharmD, NorthStar Chad Nicholson, PharmD, NorthStar Emily Baker, PharmD, BCPS, NorthStar</i>
➤ New Drugs	
• Nuzyra	
• Yupelri	
• Zolgensma	
ADJOURNMENT OF OPEN SESSION	<i>Vice-Chair</i>
EXECUTIVE SESSION	<i>Nina Bandali, PharmD, Pharmacist Account Manager, Magellan Rx Management</i>
RECONVENING OF OPEN SESSION	<i>Vice-Chair</i>
BOARD'S RECOMMENDATIONS AND VOTES	<i>Vice-Chair</i>
FUTURE AGENDA ITEMS	<i>Vice-Chair</i>
ADJOURNMENT OF MEETING	<i>Vice-Chair</i>

This page intentionally left blank

**Department of Community Health
Drug Utilization Review Board (DURB)
MINUTES
Tuesday, May 7, 2019**

MEMBERS PRESENT

Burton L. Lesnick, M.D., FAAP, Chair
M. Celeste Fowler, Pharm.D., Vice-Chair
Doug Collins, M.D.
Alton Condra III, R.Ph.
Gurinder Doad, M.D.
Rod M. Duraski, M.D., FACP, MBA
Robyn Lorys, Pharm.D.
J. Russell May, Pharm.D.
Osgood (Drew) A. Miller, R.Ph.
Brent L. Rollins, R.Ph., Ph.D.

MEMBERS ABSENT

Mia Avery, Pharm.D.
Glenda Wrenn Gordon, M.D.
Matthew Perri, R.Ph., Ph.D.
Danny A. Toth, R.Ph.

Staff

Peter D’Alba, R.Ph., Pharmacy Director, Pharmacy Services
Gilletta Gray, R.Ph., Clinical Manager, Pharmacy Services
Maria Lucas, Pharmacy Program Specialist, Pharmacy Services
Rebecca Morrison, Pharmacy Program Specialist, Pharmacy Services
Rose Marie Duncan, MBA, Operations Analyst-Drug Rebate Program, Pharmacy Services
Lori Garner, MHS, MBA, R.Ph., Pharmacist, SHBP

NorthStar HealthCare Consulting

Emily Baker, Pharm.D., BCPS, MHA, MBA, President
Afzal “Fez” Mistry, Pharm.D., Clinical Programs Director
Chad Nicholson, Pharm.D., Clinical Pharmacist

OptumRx

Mark Hall, MBA, PMP, Assoc. Director, Government and Public Sector Markets
Talmahjia “Tami” Sweat, Pharm.D., Director, Clinical Management

Magellan Rx Management

Chris Andrews, Pharm.D., VP, Pharmacy Pricing and Value Based Purchasing
Nina Bandali, Pharm.D., Pharmacist Account Manager

Call to Order

The Drug Utilization Review Board (DURB/DUR Board/Board) held its second meeting for the calendar year on May 7, 2019. The Chair, Burton L. Lesnick, M.D., FAAP, called the meeting to order at 10:00am.

Minutes from the Previous Meeting

Chair Lesnick asked for corrections or changes to the minutes from the March 5, 2019 meeting. A motion was made (Osgood (Drew) A. Miller, R.Ph.), seconded (J. Russell May, Pharm.D.), and carried to approve the minutes as written.

External Comments Session

External comments were presented to the Board from the following noted below:

- Charles “Chip” Hearn, Jr. (Hemophilia A patient) – shared his personal story about his condition and treatment experiences and asked for consideration of coverage for all antihemophilic agents.
- Jeff Cornett (VP, Research and Public Policy, Hemophilia of Georgia) – stressed the importance of patients having access to full range of antihemophilic drugs.
- Neil Campbell (Executive Director, Georgia Council on Substance Abuse – supported access to medications to support addiction recovery.

Disclosure forms were completed by Charles Hearn, Jeff Cornett and Neill Campbell and were reviewed by the Department.

New Drug Reviews

Clinical information for the following new drugs, in the market six months or more, was presented for discussion and recommendations. The complete detailed drug summary is in the New Drugs for Review section of the DUR Board binder.

Therapeutic Class	Drugs	Presenter
Antimigraine Agents, Other	<i>Ajovy, Emgality</i>	Afzal “Fez” Mistry, Pharm.D.
HIV/AIDS	<i>Delstrigo, Pifeltro</i>	Afzal “Fez” Mistry, Pharm.D.
Thrombopoiesis Stimulating Proteins, Single	<i>Doptelet, Mulpleta</i>	Chad Nicholson, Pharm.D.
Cytokine and CAM Antagonists	<i>Ilumya</i>	Afzal “Fez” Mistry, Pharm.D.
Hemophilia Treatment	<i>Jivi</i>	Chad Nicholson, Pharm.D.
Cytokine and CAM Antagonists	<i>Olumiant</i>	Afzal “Fez” Mistry, Pharm.D.
Antivirals, Oral	<i>Xofluza</i>	Chad Nicholson, Pharm.D.

The Board discussed the drug information, provided comments, and raised questions on the following:

- Ajovy/Emgality – similar decrease in monthly migraines with Level A drugs; development of antibodies noticed in clinical trials, so there would be reduced efficacy, rate may be low; guidelines vague for women planning to get pregnant; good to see this

**Department of Community Health
Drug Utilization Review Board (DURB)**

MINUTES

Tuesday, May 7, 2019

targeted mechanism of action; would be good to see real world data; limited Medicaid access to neurologists; eventually primary care physicians will be prescribing.

- Pifeltro/Delstrigo – length of therapy to step through can be left up to prescriber; step approach should be reasonable to balance budget and get patients the best care; pathway to coverage for treatment experienced patients; for patients that fail a therapy, no longer considered treatment naïve; don't have to put specified time for length of therapy if stepping through; at Grady, try to have as few barriers as possible for prescribing.
- Ilumya – most agents are subcutaneous probably because of ease of administration, less painful
- Doptelet, Mulpleta – off label use would get denied on initial request and handled on appeal; Doptelet is seeking an indication for ITP; concern if large bottle sizes (current sizes are 10 and 15).
- Xofluza – age under 12 not studied; PA criteria barrier if med is to be started immediately so criteria could be amended during season if needed and monitor for Tamiflu resistance; testing-would be good to have test confirmation, testing can be expensive, some not as accurate; Tamiflu resistance-data generated by surveillance; no data for use in severely ill patients; no indication for prophylaxis.

DCH Decisions

DCH Decisions from the March 2019 DUR Board meeting were provided in the DCH Decision section of the DUR Board binder.

Upcoming Meetings

The following upcoming meetings were published in the DURB binder:

- Drug Utilization Review Board
2 Peachtree Street NW
5th Floor Board Room
Atlanta, Georgia 30303

Tuesday, August 6, 2019

Tuesday, November 5, 2019

Disclosure Forms

Disclosure forms were received and reviewed by the Department for completeness for all Board members attending the meeting.

Adjournment of Open Session

The DUR Board voted to close the open meeting pursuant to the Open Meeting Act of Georgia Section 50-14-1 – 50-14-6 and pursuant to Federal Law Section 1396R-8B3D. The individuals recorded in attendance with the Board members were from the Department of Community Health, Magellan Rx Management, NorthStar HealthCare Consulting, and OptumRx. Alexa Ray, Pharm.D. (Piedmont) and Sangita Doad, R.N. also attended the closed session with Board members. A motion was made by Robyn Lorys, Pharm.D. and seconded by Osgood (Drew) A. Miller, R.Ph. to adjourn the open session and approve the closed session. There was a

**Department of Community Health
Drug Utilization Review Board (DURB)
MINUTES**

Tuesday, May 7, 2019

unanimous vote approving the closed session. The Chairman, Burton L. Lesnick, M.D., FAAP, adjourned the open session at approximately 12:06pm, at which time members took a break then reconvened for the executive (closed) session.

Executive Session

The Executive Session was held from 12:15pm to 1:10pm.

Reconvening of Open Session

The DUR Board reconvened for the open session at 1:11pm.

Board's Recommendations to the Department

After all clinical and financial evaluations and discussions, the DUR Board voted and presented the Department with the following recommendations for changes to the Preferred Drug List (PDL) as noted in Attachment A. All motions and votes are noted in Attachment B.

Future Agenda Items

There were no future agenda items noted.

Conclusion

At the conclusion of the reconvened open session and no other business for discussion, there was a unanimous decision to adjourn the meeting (motion made by Osgood (Drew) A. Miller, R.Ph. and seconded by J. Russell May, Pharm.D.). Chair Lesnick adjourned the meeting at 1:17pm.

THESE MINUTES ARE HEREBY APPROVED AND ADOPTED, THIS THE _____
DAY OF _____, 2019.

Burton L. Lesnick, M.D., FAAP, Chair



The Drug Utilization Review (DUR) Board Reviewed
the Following New Drugs/Classes on
May 7, 2019

Therapeutic Class	Drug Name	DURB Recommendations
Antimigraine Agents, Other		
	<i>Ajovy (Subcutaneous) Injection</i>	NP/PA
	<i>Emgality (Subcutaneous) Injection</i>	NP/PA
HIV/AIDS		
	<i>Delstrigo (Oral) Tablet</i>	NP/PA
	<i>Pifeltro (Oral) Tablet</i>	NP/PA
Cytokine & CAM Antagonists		
	<i>Olumiant (Oral) Tablet</i>	NP/PA
	<i>Ilumya (Subcutaneous) Injection</i>	NP/PA (for coverage on the PADL)
	<i>Remicade (Intravenous) Injection</i>	NP/PA (for coverage on the PADL)
	<i>Renflexis (Intravenous) Injection</i>	P/PA (for coverage on the PADL)
Thrombopoiesis Stimulating Proteins, Single		
	<i>Mulpleta (Oral) Tablet</i>	P/PA
	<i>Doptelet (Oral) Tablet</i>	NP/PA
Hemophilia Treatments		
	<i>Advate (Intravenous) Injection</i>	P
	<i>Afstyla (Intravenous) Injection</i>	P
	<i>Jivi (Intravenous) Injection</i>	NP/PA
	<i>Koate (Intravenous) Injection</i>	NP/PA
	<i>Monoclate-P (Intravenous) Injection</i>	NP/PA
Antivirals, Oral		
	<i>Xofluza (Oral) Tablet</i>	NP/PA

DURB=Drug Utilization Review Board; P=preferred; NP=non-preferred; PA=prior authorization;
PADL=Providers' Administered Drug List

This page intentionally left blank

Drug Utilization Review Board

Motions - Votes - **New Drugs**

November 6, 2018

New Drug	Drug	PDL Status	Motion - Recommendations	Additional Comments	
Antimigraine Agents, Other	Ajovy (Subcutaneous) Injection	N/A	NP/PA	Step through will include accomodations for pregnant women and women of child bearing age	
	Emgality (Subcutaneous) Injection	N/A	NP/PA		
Board Members - Present	Motion Maker (v)	Seconded By (v)	VOTES		
<i>(Strike out, when absent)</i>			YES (v)	NO (v)	ABSTAIN (v)
1	Avery, Mia, Pharm.D.				
2	Collins, Douglas, M.D.		✓		
3	Condra III, Alton, R.Ph.		✓		
4	Doad, Gurinder J.S., M.D.		✓		
5	Duraski, Rod, M.D.	✓	✓		
6	Fowler, M. Celeste, Pharm.D. - Vice		✓		
7	Gordon, Glenda Wrenn, M.D.				
8	Lesnick, Burton, M.D. - Chair				
9	Lorys, Robyn Pharm.D.		✓		
10	May, J. Russell (Rusty)	✓	✓		
11	Miller, Osgood (Drew) A., R.Ph.		✓		
12	Perri, Matthew, R.Ph., Ph.D.				
13	Rollins, Brent L., R.Ph., Ph.D.		✓		
14	Toth, Danny, R.Ph.				
TOTAL			9	0	0

Drug Utilization Review Board

Motions - Votes - **New Drugs**

November 6, 2018

New Drug	Drug	PDL Status	Motion - Recommendations	Additional Comments	
HIV/AIDS	Delstrigo (Oral) Tablet	N/A	NP/PA	PA criteria for Tivicay/Triumeq will include Biktarvy step for treatment naïve patients	
	Pifeltro (Oral) Tablet	N/A	NP/PA		
Board Members - Present	Motion Maker (v)	Seconded By (v)	VOTES		
<i>(Strike out, when absent)</i>			YES (v)	NO (v)	ABSTAIN (v)
1 Avery, Mia, Pharm.D.					
2 Collins, Douglas, M.D.			√		
3 Condra III, Alton, R.Ph.		√	√		
4 Doad, Gurinder J.S., M.D.			√		
5 Duraski, Rod, M.D.			√		
6 Fowler, M. Celeste, Pharm.D. - Vice			√		
7 Gordon, Glenda Wrenn, M.D.					
8 Lesnick, Burton, M.D. - Chair					
9 Lorys, Robyn Pharm.D.	√		√		
10 May, J. Russell (Rusty)			√		
11 Miller, Osgood (Drew) A., R.Ph.			√		
12 Perri, Matthew, R.Ph., Ph.D.					
13 Rollins, Brent L., R.Ph., Ph.D.			√		
14 Toth, Danny, R.Ph.					
TOTAL			9	0	0

Drug Utilization Review Board

Motions - Votes - **New Drugs**

November 6, 2018

New Drug	Drug	PDL Status	Motion - Recommendations	Additional Comments		
Cytokine & CAM Antagonists	Olumiant (Oral) Tablet	N/A	NP/PA			
	Ilumya (Subcutaneous) Injection	N/A	NP/PA/PADL	For Coverage on the Provider Administered Drug List (PADL)		
	Remicade (Intravenous) Injection	P/PA/PADL	NP/PA/PADL	For Coverage on the Provider Administered Drug List (PADL)		
	Renflexis (Intravenous) Injection	N/A	P/PA/PADL	For Coverage on the Provider Administered Drug List (PADL)		
Board Members - Present	Motion	Seconded	VOTES			
<i>(Strike out when absent)</i>	Maker (v)	By (v)	YES (v)	NO (v)	ABSTAIN (v)	
1 Avery, Mia, Pharm.D.						
2 Collins, Douglas, M.D.			√			
3 Condra III, Alton, R.Ph.			√			
4 Doad, Gurinder J.S., M.D.	√		√			
5 Duraski, Rod, M.D.			√			
6 Fowler, M. Celeste, Pharm.D. - Vice			√			
7 Gordon, Glenda Wrenn, M.D.						
8 Lesnick, Burton, M.D. - Chair						
9 Lorys, Robyn Pharm.D.			√			
10 May, J. Russell (Rusty)			√			
11 Miller, Osgood (Drew) A., R.Ph.			√			
12 Perri, Matthew, R.Ph., Ph.D.						
13 Rollins, Brent L., R.Ph., Ph.D.		√	√			
14 Toth, Danny, R.Ph.						
TOTAL			9	0	0	

Drug Utilization Review Board

Motions - Votes - **New Drugs**

November 6, 2018

New Drug	Drug	PDL Status	Motion - Recommendations	Additional Comments	
Thrombopoiesis Stimulating Proteins, Single	Mulpleta (Oral) Tablet	N/A	P/PA		
	Doptelet (Oral) Tablet	N/A	NP/PA		
Board Members - Present	Motion	Seconded	VOTES		
(Strike out, when absent)	Maker (v)	By (v)	YES (v)	NO (v)	ABSTAIN (v)
1 Avery, Mia, Pharm.D.					
2 Collins, Douglas, M.D.	√		√		
3 Condra III, Alton, R.Ph.			√		
4 Doad, Gurinder J.S., M.D.			√		
5 Duraski, Rod, M.D.			√		
6 Fowler, M. Celeste, Pharm.D. - Vice			√		
7 Gordon, Glenda Wrenn, M.D.					
8 Lesnick, Burton, M.D. - Chair					
9 Lorys, Robyn Pharm.D.			√		
10 May, J. Russell (Rusty)			√		
11 Miller, Osgood (Drew) A., R.Ph.		√	√		
12 Perri, Matthew, R.Ph., Ph.D.					
13 Rollins, Brent L., R.Ph., Ph.D.			√		
14 Toth, Danny, R.Ph.					
TOTAL			9	0	0

Drug Utilization Review Board

Motions - Votes - **New Drugs**

November 6, 2018

New Drug	Drug	PDL Status	Motion - Recommendations	Additional Comments	
Hemophilia Treatments	Advate (Intravenous) Injection	NP/PA	P		
	Afstyla (Intravenous) Injection	NP/PA	P		
	Jivi (Intravenous) Injection	N/A	NP/PA		
	Koate (Intravenous) Injection	P	NP/PA		
	Monoclate-P (Intravenous) Injection	P	NP/PA		
Board Members - Present	Motion	Seconded	VOTES		
<i>(Strike out, when absent)</i>	Maker (v)	By (v)	YES (v)	NO (v)	ABSTAIN (v)
1 Avery, Mia, Pharm.D.					
2 Collins, Douglas, M.D.			√		
3 Condra III, Alton, R.Ph.			√		
4 Doad, Gurinder J.S., M.D.			√		
5 Duraski, Rod, M.D.	√		√		
6 Fowler, M. Celeste, Pharm.D. - Vice		√	√		
7 Gordon, Glenda Wrenn, M.D.					
8 Lesnick, Burton, M.D. - Chair					
9 Lorys, Robyn Pharm.D.			√		
10 May, J. Russell (Rusty)			√		
11 Miller, Osgood (Drew) A., R.Ph.			√		
12 Perri, Matthew, R.Ph., Ph.D.					
13 Rollins, Brent L., R.Ph., Ph.D.			√		
14 Toth, Danny, R.Ph.					

Drug Utilization Review Board

Motions - Votes - **New Drugs**

November 6, 2018

		TOTAL	9	0	0
New Drug	Drug	PDL Status	Motion - Recommendations	Additional Comments	
Antivirals, Oral		Xofluza (Oral) Tablet	N/A	NP/PA	PA Criteria-Watch for Tamiflu resistance in case of emergency
Board Members - Present		Motion Maker (v)	Secoded By (v)	VOTES	
<i>(Strike out, when absent)</i>				YES (v)	NO (v)
					ABSTAIN (v)
1	Avery, Mia, Pharm.D.				
2	Collins, Douglas, M.D.			√	
3	Condra III, Alton, R.Ph.			√	
4	Doad, Gurinder J.S., M.D.			√	
5	Duraski, Rod, M.D.			√	
6	Fowler, M. Celeste, Pharm.D. - Vice			√	
7	Gordon, Glenda Wrenn, M.D.				
8	Lesnick, Burton, M.D. - Chair				
9	Lorys, Robyn Pharm.D.			√	
10	May, J. Russell (Rusty)		√	√	
11	Miller, Osgood (Drew) A., R.Ph.	√		√	
12	Perri, Matthew, R.Ph., Ph.D.				
13	Rollins, Brent L., R.Ph., Ph.D.			√	
14	Toth, Danny, R.Ph.				
		TOTAL	9	0	0

Important Update DCH Decision Document

Listed below are Preferred Drug List changes for the State of Georgia Fee-For-Service Medicaid and PeachCare for Kids Programs

Effective July 1, 2019 (see chart below)

DCH rebate vendor Magellan Medicaid Administration (MMA) has reviewed SFY2020 supplemental rebate offers with DCH and also reviewed specific drug categories at the May 2019 DURB meeting. The PDL/PADL decisions or changes for new drugs or categories reviewed are outlined below. **Those drugs highlighted in red indicate a change from current PDL status.** For a full listing of our PDL, go to www.dch.georgia.gov/pharmacy and select the “preferred product list” option.

PREFERRED AGENTS	NON-PREFERRED AGENTS
ANTIMIGRAINE AGENTS, OTHER	
	AJOVY
	EMGALITY
ANTIVIRALS, ORAL	
	XOFLUZA
CYTOKINE AND CAM ANTAGONISTS	
	ILUMYA (PADL)
	OLUMIANT
	REMICADE (PADL)
RENFLEXIS (PADL)	
HEMOPHILIA TREATMENT	
ADVATE	
AFSTYLA	
	JIVI
	KOATE-DVI KIT
	MONOCLATE-P KIT
HEPATITIS C TREATMENT	
	ZEPATIER
HIV / AIDS	
	DELSTRIGO

PREFERRED AGENTS	NON-PREFERRED AGENTS
	PIFELTRO
HYPOGLYCEMICS, SGLT2	
JARDIANCE	
LAXATIVES & CATHARTICS	
	SUPREP
THROMBOPOIESIS STIMULATING PROTEINS	
	DOPTELET
MULPLETA	

**Georgia Department of Community Health (GDCH)
Opportunities for Pharmaceutical Manufacturer Input on Clinical
Recommendations and Clinical Management Strategies by the
Drug Utilization Review Board**

Clinical Information and Clinical Management Strategies relevant to the GDCH Medicaid Fee-For-Service program will be presented to the Drug Utilization Review Board (DURB) at each meeting through OptumRx by its vendor NorthStar HealthCare Consulting (NHC). Manufacturer input on new and existing drugs is welcomed and appreciated using these opportunities. **Please note that new drug entities are generally not reviewed by the DURB until the drug has been on the market for at least 6 months.**

Ongoing Opportunity:

DUR Board Meeting Process: Drugs, therapeutic classes and/or supplemental rebate classes under review will be posted to the DCH website at <http://dch.georgia.gov/durb-meeting-information> approximately 30 days prior to the Manufacturers' Forum. Input specific to the drugs under review from manufacturers are made directly to NHC via GAMedicaid@nhc-llc.com and reported as appropriate by NHC at subsequent DURB meetings. NHC will pass relevant manufacturer-submitted electronic materials to the DURB members via a secure FTP site.

Upon review of information, and based on its expertise and discussions, the DURB makes recommendations to GDCH.

Opportunity to Appeal to GDCH:

GDCH Review Process: DURB recommendations are reviewed by GDCH for final decisions. Manufacturers may request an appeal meeting directly with GDCH after conclusion of each quarterly DURB meeting and **this appeal meeting must be conducted within 10 business days following the DURB meeting.** **Contact: Shirmary Hodges at (404) 656-4044 or shodges@dch.ga.gov**

Presentation Opportunity:

Manufacturers' Forum: A forum prior to each relevant DURB meeting whereby manufacturers may present:

- 1) Clinical information relevant to a new drug on the market or a drug that is part of a therapeutic or supplemental rebate class under review by the DURB at the next meeting.
- 2) Clinical information relevant to ongoing NHC/OptumRx clinical management strategies (e.g. review of drug benefit plan designs, new drugs coming to market, new indications, etc.) as deemed necessary by NHC/OptumRx.

Please see the Manufacturers' Forum Announcement at <http://dch.georgia.gov/durb-meeting-information>.

**Questions not addressed in this document may be sent to NorthStar
HealthCare Consulting by e-mail: GAMedicaid@nhc-llc.com**

This page intentionally left blank

2019

Upcoming Meetings

Drug Utilization Review Board Meeting

2 Peachtree Street, N.W.

5th Floor Board Room

Atlanta, Georgia 30303

Tuesday, March 5, 2019: 10:00am – 2:00pm

Tuesday, May 7, 2019: 10:00am – 3:00pm

Tuesday, August 6, 2019: 10:00am – 2:00pm

Tuesday, November 5, 2019: TBD

This page intentionally left blank

Drug Utilization Review Board

Board Member	Credentials	Specialty/Area of Expertise	Company Name
Burton L. Lesnick, Chair	M.D., FAAP	Pediatrics/Pediatric Pulmonology	Children's Healthcare of Atlanta
M. Celeste Fowler, Vice-Chair	Pharm.D., HCMBA	340B Pharmacy	Piedmont Henry Hospital
Mia Avery	Pharm.D.	Oncology Pharmacy	Emory University Hospital Winship Cancer Institute
Douglas C. Collins	M.D.	Hematology/Oncology	Metro Hematology-Oncology, PC
Alton Condra III	R.Ph.	HIV/AIDS Pharmacy - Infectious Disease Program	Grady Memorial Hospital
Gurinder J.S. Doad	M.D., Ph.D.	Family Practice	Southwest Georgia Family Medicine and Mercer University School of Medicine
Rod M. Duraski	M.D., FACP, MBA	Internal Medicine	West Georgia Health
Glenda Gordon	M.D.	Psychiatry, Academia - Professor	Morehouse School of Medicine
Robyn Lorys	Pharm.D.	Academia - Professor	Mercer University College of Pharmacy
J. Russell May	Pharm.D.	Academia - Professor	University of Georgia College of Pharmacy
Drew A. Miller	R.Ph.	Retail Pharmacy	Wynn's Pharmacy
Matthew Perri III	Ph.D., R.Ph.	Academia - Professor	University of Georgia College of Pharmacy
Brent L. Rollins	R.Ph., Ph.D.	Academia - Professor	Philadelphia College of Osteopathic Medicine School of Pharmacy
Danny A. Toth	R.Ph.	Pharmacy Benefit Plans	Timber Ridge Consultants, LLC